Posttransplant primary cutaneous Ki-1 (CD30)+/CD56+ anaplastic large cell lymphoma.
An anaplastic large cell lymphoma that was negative for Epstein-Barr virus and positive for Ki-1 (CD30) presented as a polypoid scalp mass in a 56-year-old man 16 years after renal transplantation. The lymphoma was of the CD4+ cytotoxic T-cell lineage, and the tumor cells also expressed CD56. Despite reduction in the dose of immunosuppression and localized radiotherapy, the tumor had rapidly progressed to involve the soft tissue of the right hand. Systemic chemotherapy induced complete regression of the soft tissue lesion. This case illustrates that posttransplant primary cutaneous CD30+ anaplastic large cell lymphomas may assume an aggressive clinical course but can still be controlled by systemic chemotherapy.
Kim
Hee Kyung
HK
Department of Pathology, Brain Korea 21 Project for Medical Science, College of Medicine, Yonsei University, Seoul, Korea.
Jin
So-Young
SY
Lee
Nam Su
NS
Won
Jong Ho
JH
Park
Hee Sook
HS
Yang
Woo Ick
WI
D000951:Antigens, Neoplasm / Q000032:analysis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001379:Azathioprine / Q000008:administration & dosage / Q000009:adverse effects; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology / Q000473:pathology; D019002:CD56 Antigen / Q000032:analysis; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D016572:Cyclosporine / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000473:pathology* / Q000532:radiotherapy; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D016030:Kidney Transplantation / Q000276:immunology; D017728:Lymphoma, Large-Cell, Anaplastic / Q000188:drug therapy / Q000276:immunology / Q000473:pathology* / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000188:drug therapy / Q000276:immunology / Q000473:pathology* / Q000532:radiotherapy; D011239:Prednisolone / Q000008:administration & dosage / Q000009:adverse effects; D012074:Remission Induction; D012535:Scalp / Q000473:pathology*; D012878:Skin Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000473:pathology* / Q000532:radiotherapy; D014750:Vincristine / Q000008:administration & dosage
D000951:Antigens, Neoplasm; D019002:CD56 Antigen; D007166:Immunosuppressive Agents; D014750:Vincristine; D004317:Doxorubicin; D016572:Cyclosporine; D003520:Cyclophosphamide; D011239:Prednisolone; D001379:Azathioprine